Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.
about
Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.
P2860
Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@ast
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@en
type
label
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@ast
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@en
prefLabel
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@ast
Abatacept decreases disease ac ...... lagen-induced arthritis model.
@en
P2093
P2860
P1476
Abatacept decreases disease ac ...... llagen-induced arthritis model
@en
P2093
Diahann T S L Jansen
Hanane el Bannoudi
Jeroen N Stoop
Kim L L Habets
Marjolijn Hameetman
Ramon Arens
Tom W J Huizinga
P2860
P2888
P356
10.1186/S13075-015-0731-1
P50
P577
2015-08-20T00:00:00Z
P5875
P6179
1037780845